Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S908000, C514S922000
Reexamination Certificate
active
10753665
ABSTRACT:
A method of treating cancer is provided comprising administering an amount of etodolac or analog theteof to a subject afflicted with leukemia that is effective to reduce the viability and/or to sensitize leukemia cells to an anti-cancer agent.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 1299577 (1992-04-01), None
patent: 2226340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: WO-96/28148 (1996-09-01), None
patent: WO-9748391 (1997-12-01), None
patent: WO-98/09603 (1998-03-01), None
patent: WO-98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: WO-00/02555 (2000-01-01), None
patent: WO-00/13410 (2000-03-01), None
patent: WO-0106990 (2001-02-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-0212188 (2002-02-01), None
Berkow et al, “The Merck Manual of Medicial Information”, Merck Research Laboratories Publishing, pp. 765-766 and 779-780 (1997).
Heath, Clark W., “Nonsteroidal Antiinflammatory Drugs and Human Cancer”,American Cancer Society,vol. 74, No. 10, (Nov. 15, 1994),2885-2886.
Leman, Eddy S., et al., “Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer”,Journal of Cellular Biochemistry, 86,(2002),203-212.
McCracken, John D., “Antiproliferative Effects of the Enantiomers of Flurbiprofen”,Journal of Clinical Pharmacology,(1996),540-545.
Piazza, Gary A., “Apoptois Primarily Accounts for the Growth-inhibitory Properties of Sulindac Metabolites and Involves a Mechanism That is Independent of Cyclooxygebase Inhibiton, Cell Cycles Arrest, and p53 Induction”,Cancer Research,vol. 57, (Jun. 15, 1997),2452-2459.
Riley, et al., “New Drugs: a six month review”,US Pharamacist,vol. 16, (Sep. 1991),35-64.
Thun, Michael J., “Aspirin, NSAIDs, and digestive tract cancers”,Cancer and Metastasis Reviews 13, Kluwer Academic Publishers.,(1994),269-277.
Wechter, William J., “R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer”,Inflammopharmacology,vol. 8, No. 2, (2000), 189-206.
Wechter, William J., “R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APC min/+ Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer”,Cancer Research,vol. 57, No. 19, (Oct. 1, 1997),4316-4324.
Wechter, William J., “Rac-Flurbiprofen Is More Ulcerogenic Than Its (S)-Enantiomer”,Chirality,vol. 5, No. 7, (1993),492-494.
The Merck Index, Eleventh Edition,Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., Entry No. 3831—“ Etodolac”,(1989),p. 608.
In: Remington's Pharmaceutical Sciences, Eighteenth Edition,Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1121.
Abramson, S. B., et al., “The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism, 32(1), (Jan. 1989),pp. 1-9.
Alexanian, R., et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine,330 (7), (Feb. 17, 1994),pp. 484-489.
Barlogie, B , et al., “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”,Blood, 72,(1988),2015-2019.
Bataille, R , et al., “Multiple Myeloma”,New England Journal of Medicine, 336,(1997),1657-1664.
Becker-Scharfenkamp, U. , et al., “Evaluation of the Steroselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621(2), (Nov. 24, 1993),pp. 199-207.
Bellosillo, B. , et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92(4), (Aug. 15, 1998),pp. 1406-1414.
Berendes, U. , et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine”,Enantiomer, 1,Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996),415-422.
Brenna, E. , et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53,(1997),17769-17780.
Brocks, D. R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26(4), (1994),pp. 259-274.
Carson, D. A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proc. Natl. Acad. Sci. USA, 89(7), (Apr. 1992),pp. 2970-2974.
Chinetti, G. , et al., “Activation of Proliferator-activated Receptors alpha and Y Induces Apoptosis of Human Monocyte-derived Macrophages”,The Journal of Biological Chemistry, 273(40), (Oct. 2, 1998),pp. 25573-25580.
Cunningham, D , et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12,(1994), 764-768.
Demerson, C. A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19(3), (1976),pp. 391-395.
Demerson, C. A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26(12), (Dec. 1983),pp. 1778-1780.
Drachenberg, D. E., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy and Cryoablation”,Seminars in Surgical Oncology, 18(1), (Jan./Feb. 2000),pp. 37-44.
Duffy, C. P., et al., “Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDSs)”,European Journal of Cancer, 34(8), (Jul. 1998),pp. 1250-1259.
Hahnfeld, L. E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient, 83(5), (Sep. 1999),pp. 1231-1245.
Haroussaeu, J. L., et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood, 79(11), (Jun. 1, 1992), pp. 2827-2833.
Krajewski, S. , et al., “Detection of Multiple Antigens on Western Blots
Adachi Soichi
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Krass Frederick
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Use of etodolac for the treatment of chronic lymphocytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of etodolac for the treatment of chronic lymphocytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of etodolac for the treatment of chronic lymphocytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801564